# Miltefosine for Brazilian Visceral Leishmaniasis

> **NCT00378495** · PHASE1,PHASE2 · TERMINATED · sponsor: **AB Foundation** · enrollment: 80 (estimated)

## Conditions studied

- Kala Azar

## Interventions

- **DRUG:** Miltefosine: initially 2.5 mg/kg/day for 28 days

## Key facts

- **NCT ID:** NCT00378495
- **Lead sponsor:** AB Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2007-04
- **Final completion:** 2007-10
- **Target enrollment:** 80 (ESTIMATED)
- **Why stopped:** accrual criteria being reviewed
- **Last updated:** 2016-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378495, "Miltefosine for Brazilian Visceral Leishmaniasis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00378495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*